A study highlighted the accuracy of three leading continuous glucose monitors (CGM), including systems from Abbott and Dexcom.

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.

Blue Cross Blue Shield of Massachusetts announced that it expanded its care options for members with diabetes.

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

Medtronic (NYSE:MDT) issued an urgent field safety notice in Europe related to multiple versions of its MiniMed insulin pump ...